Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

Ursula A. Matulonis, MD
Published: Monday, Mar 26, 2018


Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

The phase I/II trial, which enrolled 62 women, identified the recommended phase II dose of niraparib at 200 mg daily and pembrolizumab at 200 mg daily.

In women with platinum-resistant ovarian cancer who do not have a BRCA mutation, there was a 26% response rate. Matulonis notes that this result is noteworthy, as single-agent response rates with PARP inhibitors or immunotherapy agents in this patient population are under 10%. In women with platinum-resistant ovarian cancer who do have a BRCA mutation, there was a 29% response rate.

These results are very exciting, and Matulonis says she believes this combination should move forward into larger clinical testing.

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

The phase I/II trial, which enrolled 62 women, identified the recommended phase II dose of niraparib at 200 mg daily and pembrolizumab at 200 mg daily.

In women with platinum-resistant ovarian cancer who do not have a BRCA mutation, there was a 26% response rate. Matulonis notes that this result is noteworthy, as single-agent response rates with PARP inhibitors or immunotherapy agents in this patient population are under 10%. In women with platinum-resistant ovarian cancer who do have a BRCA mutation, there was a 29% response rate.

These results are very exciting, and Matulonis says she believes this combination should move forward into larger clinical testing.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor TypesDec 31, 20181.5
Oncology Briefings™: New Frontiers in the Treatment of MSI High Endometrial CancerDec 31, 20181.0
Publication Bottom Border
Border Publication
x